Search
Ecallantide
go.drugbank.com/drugs/DB05311ApprovedApart from its FDA and EMA indication, ecallantide has been used off label in the management of nonhistaminergic angioedema, not due to HAE [A32017].
GI-5005
go.drugbank.com/drugs/DB05942InvestigationalTarmogens are believed to activate both an innate immune response via Toll-like receptors (TLRs), as well as an adaptive, antigen specific cellular immune response.
Soy isoflavones
go.drugbank.com/drugs/DB14101ApprovedMixtures: D-Cal SoyCal, ISOFLAVONA DE SOYA + VITAMINA D300 UI +CITRATO DE CALCIO.Diazoxide
go.drugbank.com/drugs/DB01119ApprovedInvestigational[A190372] Diazoxide is commonly used in the treatment of hyperinsulinaemic hypoglycemia due to its ability to inhibit insulin release.
Bromothalonil
go.drugbank.com/drugs/DB14199ApprovedIt is also a known allergen and dermatological irritant that has been banned in many EU countries due to increasing rates of contact allergy [A34322].
Dimetindene
go.drugbank.com/drugs/DB08801ApprovedInvestigationalDimetindene (Fenistil) is an antihistamine/anticholinergic used orally and locally as an antipruritic.
Vaborbactam
go.drugbank.com/drugs/DB12107ApprovedInvestigationalVaborbactam is a β-lactamase inhibitor based on a cyclic boronic acid pharmacophore. It has been used in trials investigating the treatment of bacterial infections in subjects with varying degrees of renal insufficiency. In August 2017, ...
Saxagliptin
go.drugbank.com/drugs/DB06335ApprovedInvestigationalSaxagliptin (rINN) is an orally active hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. FDA approved on July 31, 2009.
VPM4001
go.drugbank.com/drugs/DB05089ExperimentalIt consists of irradiated human LNCaP cells that have been genetically modified to permanently secrete interferon-γ and interleukin-2 (LNCaP/IL-2/IFN-γ).
RO7296682
go.drugbank.com/drugs/DB17531InvestigationalRO7296682 is a monoclonal antibody against CD25 (IL-2R alpha) expressed on tumour-infiltrating regulatory T (T<sub>reg</sub>) cells.